Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...1112131415161718192021...5960»
  • ||||||||||  thyroxine / Generic mfg., hydrocortisone / Generic mfg.
    Review, Journal:  A rare pituitary tumor associated with hyperthyroidism and acromegaly. (Pubmed Central) -  Jan 10, 2023   
    The diagnosis of mixed pituitary TSH/GH adenoma must be combined with clinical manifestations, immunohistochemical staining and relevant hormone levels, and genetic testing if necessary for comprehensive judgment. For patients with large adenomas, it is recommended to use somatostatin analogs to restore TH levels and control the excessive secretion of GH levels before surgery.
  • ||||||||||  Journal:  Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study. (Pubmed Central) -  Jan 9, 2023   
    In those patients treated only after neurosurgery due to persistent GH-hypersecretion (51, 53.1%) the absence of any appreciable adenomatous remnant on postoperative MRI was associated with a negligible risk of resistance (OR 0.04, p = 0.003). In the Italian acromegaly population, a low-grade SSTR2 expression seems to be the most relevant predictor of resistance to first-generation somatostatin receptor ligands, followed by a SG/intermediate cytokeratin pattern and a T2-iso/hyperintense MRI signal.
  • ||||||||||  Review, Journal:  Vertebral Fractures in Acromegaly: A Systematic Review. (Pubmed Central) -  Jan 9, 2023   
    Disease activity is an important determinant of vertebral fracture incidence and prevalence, although hypogonadism is less so. To clarify the predictive value of both BMD and TBS for vertebral fractures, additional, larger, prospective studies are necessary.
  • ||||||||||  Journal:  Acromegaly. (Pubmed Central) -  Jan 5, 2023   
    Clinical trial registration NCT02005978. No abstract available
  • ||||||||||  A MASQUERADE OF ACROMEGALY WITH UNDERLYING HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_1496;    
    Acromegalic cardiomyopathy is a known complication of excess growth hormone secretion, but the severity of septal hypertrophy in our patient suggested another, simultaneous disease process. This case highlights the importance of searching for answers for varied clinical scenarios in the same patient.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Trial termination:  Acromegaly Combination Treatment Study (clinicaltrials.gov) -  Jan 4, 2023   
    P=N/A,  N=76, Terminated, 
    Completed --> Terminated; Review of the 12-month data showed patients who deviated from protocol with full IRB monitoring and reporting could not be optimally analyzed. Reopening the study for new enrollment is not feasible and the study was terminated with IRB approval.
  • ||||||||||  Acromegaly (Twitter) -  Jan 2, 2023   
  • ||||||||||  Acromegaly (Twitter) -  Dec 31, 2022   
  • ||||||||||  Acromegaly (Twitter) -  Dec 30, 2022   
  • ||||||||||  Acromegaly (Twitter) -  Dec 30, 2022   
  • ||||||||||  Acromegaly (Twitter) -  Dec 30, 2022   
  • ||||||||||  Acromegaly (Twitter) -  Dec 30, 2022   
  • ||||||||||  Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1 (Exhibit Hall B; 37) -  Dec 29, 2022 - Abstract #USCAP2023USCAP_1364;    
    We report a large series of rare multilineage PitNETs expressing PIT1 and SF1. These tumors have variable clinical and morphological features, most often presenting as large tumors with GH excess and occasionally as one of multiple synchronous tumors.
  • ||||||||||  Journal:  Looking at the spine in controlled Acromegaly. (Pubmed Central) -  Dec 28, 2022   
    Management of spine osteopathy and arthropathy in acromegaly could be challenging since both complications can persist or even progress after biochemical control of disease. This article analyzes the latest evidence about possible pathophysiological links between VFs and spine arthropathy in active and controlled acromegaly, as well as the diagnostic and therapeutic aspects concerning the holistic management of acromegalic osteo-arthropathy.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Mycapssa (octreotide) / Amryt
    Review, Journal:  Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals. (Pubmed Central) -  Dec 24, 2022   
    Sodium salcaprozate (SNAC) and sodium caprylate (C8) have been used as gastrointestinal permeation enhancers for semaglutide and octreotide, respectively. Herein, we briefly review two approved products, Rybelsus and Mycapssa, and discuss the permeation properties of SNAC and medium chain fatty acids, sodium caprate (C10) and C8, focusing on Eligen technology using SNAC, TPE technology using C8, and gastrointestinal permeation enhancement technology (GIPET) using C10.
  • ||||||||||  Review, Journal:  Molecular targets in acromegaly. (Pubmed Central) -  Dec 23, 2022   
    The degree of control is variable: however, correlates with both disease aggressiveness and tumor factors that predict treatment response including somatostatin receptor subtype expression, granulation pattern, kinases and their receptors, and other markers of proliferation. A better understanding of the mechanisms underlying these molecular markers and their relationship to outcomes holds promise for expanding treatment options as well as a more personalized approach to treating patients with acromegaly.
  • ||||||||||  Review, Journal:  Lumbar Spinal Canal Stenosis in Acromegaly: A Case Report and Literature Review. (Pubmed Central) -  Dec 9, 2022   
    Lumbar magnetic resonance imaging showed disc bulging at L3/4 and 4/5, and he was diagnosed with lumbar spinal canal stenosis due to hypertrophy of the yellow ligament. Patients with acromegaly may complain of osteoarthropathy, so we must pay attention to the symptoms of spinal canal stenosis in collaboration with orthopedic specialists.
  • ||||||||||  Review, Journal:  Growth and Growth Hormone through the Ages: Art and Science. (Pubmed Central) -  Nov 30, 2022   
    The efforts of basic scientists led to the extraction and purification of GH. Clinical scientists have expanded the appropriate use of hGH for short children with conditions in addition to GH deficiency.
  • ||||||||||  Journal:  Corneal Tonometric and Morphological Changes in Patients with Acromegaly. (Pubmed Central) -  Nov 27, 2022   
    It proves that the eye might be sensitive to long-term overexposure to growth hormone (GH) and insulin-like growth factor-1 (IGF-1). We suggest that disease activity be taken into consideration on ophthalmological examination.
  • ||||||||||  Journal:  The coexistence of newly diagnosed acromegaly with primary empty sella: More frequent than expected? (Pubmed Central) -  Nov 26, 2022   
    The present study revealed the coexistence of newly diagnosed acromegaly with primary ES at a rate of nearly 20% which is more frequent than expected and this association is not rare. The presence of ES was not associated with any preoperative/postoperative pituitary hormone levels and remission status, except lower preoperative prolactin and nadir GH responses to OGTT.
  • ||||||||||  Journal:  Tumor-induced osteomalacia combined with acromegaly: A case report. (Pubmed Central) -  Nov 22, 2022   
    Then, we removed the pituitary adenoma of the patient, and the GH and phosphate levels returned to the normal range. Here, we report the first case with acromegaly combined with TIO, the changing process of his phosphate concentration suggests an interesting concurrent effect of excess GH and FGF23 in this rare condition.